Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 417 of 6351
-
Could a shot replace daily HIV pills? new trial tests Two-Injection combo
Disease control Recruiting nowThe study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS-3242 plus Lenacapavir (LEN) versus continuing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in virological…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis is a Phase I/II study. The Phase I part will evaluate the safety and tolerability of sonrotoclax in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), using a standard 3+3 dose-escalation design, to determine the …
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New oral drug takes on tough brain cancer in phase 3 trial
Disease control Recruiting nowThe purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Blood thinner duration trial aims to save limbs in severe artery disease
Disease control Recruiting nowChronic limb threatening ischemia (CLTI) is defined as ischemic foot pain at rest or non-healing foot wounds that is attributable to severe peripheral arterial disease (PAD).Revascularization is the cornerstone of therapy to relieve ischemic pain, prevent limb loss and preserve p…
Phase 3 • Sponsor: Fondation Hôpital Saint-Joseph • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New clotting factor aims to cut bleeding episodes in severe hemophilia a
Disease control OngoingThe indication for this product is to control and prophylaxis in patients with Hemophilia A (congenital Factor VIII deficiency): The Primary Objective: To evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylacti…
Phase 3 • Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as secon…
Early phase 1 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a blood filter sweep out hidden plastic pollution?
Knowledge-focused By invitation onlyThis prospective, non-interventional, within-subject paired biomarker study will evaluate whether circulating microplastic and nanoplastic-associated particle concentrations and PFAS concentrations in peripheral blood change after clinically prescribed double-filtration plasmaphe…
Sponsor: Proxima Health, Inc. • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
New immunotherapy combo aims to stop liver cancer return after surgery
Disease control OngoingTumor recurrence is the leading cause of death and a major bottleneck for long-term survival in patients with hepatocellular carcinoma (HCC). Therefore, there is an urgent clinical need for effective postoperative adjuvant therapies to reduce postoperative recurrence and improve …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Antioxidant supplement may boost IVF outcomes for older women
Disease control Recruiting nowFemale fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membrane…
Sponsor: Kaohsiung Veterans General Hospital. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Leukemia shot could replace long IV drips
Disease control Not yet recruitingThe main objective of this trial is to demonstrate that subcutaneous (SC) blinatumomab in conjunction with chemotherapy (Arm B) is non-inferior to continuous intravenous infusion (cIV) blinatumomab in conjunction with chemotherapy (Arm A) in overall survival (OS) in newly diagnos…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Could skipping a common antibiotic be just as safe for heart infections?
Disease control Recruiting nowThe primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months after randomization.
Phase 3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug duo targets advanced gynecologic cancers in early trial
Disease control Recruiting nowThis is a prospective, multicenter, single-arm clinical trial investigating Becotatug Vedotin in combination with Zimberelimab for the treatment of patients with recurrent and metastatic cervical cancer, vulvar cancer, and vaginal cancer. A total of 30 patients are expected to be…
Phase 2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to stop rare heart disease in its tracks
Disease control OngoingThe purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with Transthyretin-mediated amyloid cardiomyopathy…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for lung scarring: AZD8965 enters Mid-Stage trial
Disease control Recruiting nowThis Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pee test could spot colon cancer early in africa
Diagnosis Recruiting nowThe purpose of this study is to find out whether a urine test can detect colorectal cancer (CRC) and precancerous polyps in participants living in Ghana, Tanzania, and South Africa.
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to rescue PNH patients failing standard care
Disease control Recruiting nowThis study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the po…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Simple urine test could spot pancreatic cancer early
Diagnosis Recruiting nowThe main purpose of the study is to assess the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma (PDAC) the most common type of pancreatic cancer that accounts for approximately 90% of all pancreatic cancer cases. The study aims to characterize the per…
Sponsor: Urteste S.A • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New drug delivery methods tested for tough breast cancer
Disease control Not yet recruitingAn Exploratory Study on the Efficacy and Safety of Different Administration Routes of SHR-A1811 in the Treatment of HER2-Positive Advanced Breast Cancer
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to tame overactive thyroid in Graves' disease
Disease control Recruiting nowThis study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blind…
Phase 2 • Sponsor: Yarrow Bioscience, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Sniffing out cancer: new breath test could spot colon cancer before it spreads
Diagnosis Not yet recruitingThe goal of this observational study is to see whether a new, noninvasive test that analyzes smells (odor) from breath and intestinal gas can help detect colorectal cancer and precancerous growths at an early stage. The main questions it aims to answer are: Can the new odor-bas…
Sponsor: Beijing University of Chinese Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC